Clinical Trial Update: Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib plus simvastatin for prevention and treatment of respiratory failure in COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection

Drugs mentioned

• Ruxolitinib (ruxolitinib)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Fundación de investigación HM | Conditions: Coronavirus Infection | Phase 2 | Status: COMPLETED